Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Articles by Carrico J, Jia X, Zhao Y, et al. Cost-effectiveness, budget impact of tildrakizumab for the treatment of moderate to severe plaque psoriasis using 2019 drug costs [abstract L14]. J Manag Care Spec Pharm. 2019, 25(suppl 10-a):S79. doi: 10.18553/jmcp.2019.25.10-a.s1
Advertisement
Latest Updated Articles
- Abstract Recap: Cost-Effectiveness and Budget Impact of Tildrakizumab for First-Line Treatment of Plaque Psoriasis
Published: December 6th 2019 | Updated:
Advertisement
Advertisement
Trending on AJMC
1
FDA to Restrict Ingredients Used in Mass-Marketed Compounded GLP-1s, Crack Down on Misleading Ads
2
Contributor: Reimagining Beneficiary Engagement in Accountable Care Models to Make America Healthy Again
3
5 Things to Know About the Oral GLP-1 Era
4
MID Models Reduce Adverse Events, Lower Costs in Oncology: Kenneth Komorny, PharmD, BCPS
5
